Alto Neuroscience Publishes Trial Of Dopamine Agonist Pramipexole With Mood Disorders And Clinically Significant Anhedonia In Nature Medice

Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

ANRO

0.00

Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges' g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.